Trump announces trade deal with EU following months of negotiations
SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM), a prominent player in glucose biosensing technology with a market capitalization of $30.4 billion, announced on Monday the addition of Renée Galá to its Board of Directors, effective as of the previous Monday. Galá, the current President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, brings a wealth of experience in financial and strategic leadership within the life sciences sector. According to InvestingPro data, DexCom maintains strong financial health with a Piotroski score of 7, indicating robust operational efficiency.
Galá’s tenure at Jazz Pharmaceuticals, a company with over $4 billion in revenues in 2024, has seen her manage a broad range of global operations, including commercial activities, research and development, and corporate strategy. Her expertise is expected to be an asset to DexCom as it continues to pursue growth and create shareholder value. The company has demonstrated strong revenue growth with a 5-year CAGR of 22% and generated $630.7 million in levered free cash flow over the last twelve months.
Kevin Sayer, DexCom’s chairman, president, and CEO, expressed enthusiasm about Galá’s appointment, highlighting her proven track record in guiding global finance and operations. Sayer anticipates that her insights will be particularly valuable as DexCom seeks to expand its impact on metabolic health worldwide. InvestingPro analysis reveals that management has been actively buying back shares, demonstrating confidence in the company’s future prospects. Get access to 14 additional exclusive ProTips and comprehensive financial analysis through InvestingPro’s detailed research reports.
In her career, Galá has held several significant roles, including Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals from 2020 to 2023, and Chief Financial Officer of GRAIL, Inc. in 2019. She has also served as Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc. after its spin-out from Theravance, Inc. Her earlier experience includes positions at Eli Lilly and Company and in the energy industry, where she focused on corporate finance and mergers and acquisitions.
Galá’s background also includes serving as a non-executive director for various companies in the biotech and life sciences industry, such as Gossamer Bio, Gyroscope Therapeutics, and Corcept Therapeutics. She holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.
DexCom, founded in 1999, has been at the forefront of glucose monitoring technology for over two decades. The company’s biosensing products have revolutionized diabetes management, providing users with tools to better understand and manage their condition. With a gross profit margin of 60.5% and return on equity of 28%, DexCom demonstrates strong operational efficiency. Discover more detailed insights and Fair Value analysis in DexCom’s comprehensive Pro Research Report, available exclusively on InvestingPro.
This report is based on a press release statement.
In other recent news, DexCom reported fourth-quarter earnings with adjusted earnings per share of $0.45, which missed the consensus estimate of $0.52. However, the company achieved revenue of $1.11 billion, slightly surpassing the anticipated $1.1 billion, marking an 8% year-over-year increase. For the full year 2024, revenue grew by 11% to $4.03 billion, with U.S. revenue up 10% and international revenue rising 15%. DexCom has forecasted 2025 revenue of approximately $4.6 billion, slightly below the $4.61 billion consensus, while projecting a non-GAAP gross profit margin of 64-65% and a non-GAAP operating margin of about 21%.
In light of these developments, Bernstein analysts raised their price target for DexCom to $100, up from $89, while maintaining an Outperform rating. This adjustment follows DexCom’s return to stability in the latter half of 2024 and a record number of new user additions. Meanwhile, BTIG analysts have maintained their Buy rating with a $120 price target, despite a warning letter from the FDA regarding manufacturing processes. DexCom has assured that the warning does not impact its manufacturing capacity or financial projections and is actively working to address the FDA’s concerns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.